Azithromycin for early pseudomonas infection in cystic fibrosis: the OPTIMIZE randomised trial

K. Grimwood (Gold Coast (QLD), Australia)

Source: International Congress 2019 – Therapeutic breakthrough Year in review
Session: Therapeutic breakthrough Year in review
Session type: Year in review
Number: 3258
Disease area: -

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Grimwood (Gold Coast (QLD), Australia). Azithromycin for early pseudomonas infection in cystic fibrosis: the OPTIMIZE randomised trial. International Congress 2019 – Therapeutic breakthrough Year in review

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017
Year: 2018



RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017
Year: 2018



Feasibility study for a randomized controlled trial of pseudomonas aeruginosa eradication treatment in patients with bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015


Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial
Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2017




Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Source: Eur Respir J 2013; 42: 1622-1632
Year: 2013



Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Efficacy of azithromycin in severe asthma from the AMAZES randomised trial
Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Year: 2019



Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007



A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013


A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis
Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Year: 2009


Exercise training is beneficial in patients with non-cystic fibrosis bronchiectasis – A multi-centre, randomised controlled trial
Source: Annual Congress 2012 - Exercise and physical activity: towards evidence-based benefits in different populations
Year: 2012


Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013

Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017
Year: 2018



RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial)
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021


Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014


Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021